Acute versus Long-term anti-GPVI Treatment: From Receptor Blockade to Partial Downregulation
While targeting GPVI with inhibitory Fab fragments is effective and safe in acute preclinical disease settings, it is not suitable for long-term treatment. We now show that partial GPVI downregulation by low-affinity IgGs provides safe, long-term protection from thrombosis and thrombo-inflammation.
Research Communities by Springer Nature8h ago 
